U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C3H7O6P.2Na.6H2O
Molecular Weight 324.1291
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM 1-GLYCEROPHOSPHATE HEXAHYDRATE

SMILES

O.O.O.O.O.O.[Na+].[Na+].OCC(O)COP([O-])([O-])=O

InChI

InChIKey=WYHXKNIXHCIVHR-UHFFFAOYSA-L
InChI=1S/C3H9O6P.2Na.6H2O/c4-1-3(5)2-9-10(6,7)8;;;;;;;;/h3-5H,1-2H2,(H2,6,7,8);;;6*1H2/q;2*+1;;;;;;/p-2

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C3H7O6P
Molecular Weight 170.0578
Charge -2
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: DOI: 10.1042/bj0280143 DOI: 10.1042/bj0280152 http://www.wikidoc.org/index.php/Glycerol_3-phosphate

Synthetic glycerophosphates have been known for many years and have been prepared in several ways. The acid may exist in two isomeric forms, alpha and beta. The L-a-acid is the naturally occurring form; the b-acid, present in hydrolyzates of lecithins from natural sources, arises from migration of the phosphoryl group from the a-carbon atom. Dehydrogenation of L-glycerol 3-phosphate produces Dihydroxyacetone phosphate and is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway.

CNS Activity

Originator

Grimbert, L.|Bailly, O.
4
Curator's Comment: alpha-glycerophosphoric acid has long been known as a component of the lecithins and cephalins and may in a sense be looked on as a monoglyceride, the situation is much more favorable. Because of its great stability it has been possible for several workers to separate it from various phosphatides and free it from its accompanying beta-isomer. http://www.jbc.org/content/128/2/491.short

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Substrate
661
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8583
KABIVEN

Approved Use

It is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.87 mM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21986180/
80 mmol single, intravenous
dose: 80 mmol
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PHOSPHATE ION serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
38.7 mM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21986180/
80 mmol single, intravenous
dose: 80 mmol
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PHOSPHATE ION serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.06 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21986180/
80 mmol single, intravenous
dose: 80 mmol
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PHOSPHATE ION serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
[IN VITRO EFFECT OF ALPHA GLYCEROPHOSPHATE ON RELEASE OF NON-ESTERIFIED FATTY ACIDS FROM ADIPOSE TISSUE].
1965-06
[Pharmacology of glycerophosphoric acid. II. Differences in the biological action of the alpha and beta isomers in combination with thiamine or cocarboxylase].
1955-12-01
alpha-Glycerophosphoric acid and brain metabolism.
1936-01
Patents

Patents

IT 460219
4

Sample Use Guides

In Vivo Use Guide
19 to 38 mL/kg/day. The maximum infusion rate is 2.6 mL/kg/hour. Recommended infusion period is 12 to 24 hours.
Route of Administration: Intravenous
In Vitro Use Guide
Maximal ATP production in the presence of Ca2+ (200 nM) is obtained at 10 mM L-glycerol 3-phosphate in intact mitochondria from pancreatic B-cells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:01:14 GMT 2025
Edited
by admin
on Mon Mar 31 23:01:14 GMT 2025
Record UNII
GER1329YB9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
1,2,3-PROPANETRIOL, 1-(DIHYDROGEN PHOSPHATE), DISODIUM SALT, HEXAHYDRATE, (±)-
Preferred Name English
SODIUM 1-GLYCEROPHOSPHATE HEXAHYDRATE
Common Name English
DISODIUM DL-.ALPHA.-GLYCEROPHOSPHATE HEXAHYDRATE
Common Name English
GLYCEROL, 1-(DIHYDROGEN PHOSPHATE), DISODIUM SALT, HEXAHYDRATE, DL-
Common Name English
1,2,3-PROPANETRIOL, 1-(DIHYDROGEN PHOSPHATE), SODIUM SALT, HYDRATE (1:2:6)
Systematic Name English
DISODIUM DL-GLYCEROL 3-PHOSPHATE HEXAHYDRATE
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID40955904
Created by admin on Mon Mar 31 23:01:14 GMT 2025 , Edited by admin on Mon Mar 31 23:01:14 GMT 2025
PRIMARY
PUBCHEM
43835013
Created by admin on Mon Mar 31 23:01:14 GMT 2025 , Edited by admin on Mon Mar 31 23:01:14 GMT 2025
PRIMARY
FDA UNII
GER1329YB9
Created by admin on Mon Mar 31 23:01:14 GMT 2025 , Edited by admin on Mon Mar 31 23:01:14 GMT 2025
PRIMARY
CAS
34363-28-5
Created by admin on Mon Mar 31 23:01:14 GMT 2025 , Edited by admin on Mon Mar 31 23:01:14 GMT 2025
PRIMARY
Related Record Type Details
Structure of SODIUM 1-GLYCEROPHOSPHATE
ANHYDROUS->SOLVATE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966